A systematic review of patient preference elicitation methods in the treatment of colorectal cancer

被引:27
作者
Currie, A. [1 ,2 ]
Askari, A. [1 ,2 ]
Nachiappan, S. [1 ,2 ]
Sevdalis, N. [3 ,4 ]
Faiz, O. [1 ,2 ,3 ]
Kennedy, R. [1 ,2 ,3 ]
机构
[1] St Marks Hosp, Harrow HA1 3UJ, Middx, England
[2] Acad Inst, Harrow, Middx, England
[3] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London, England
[4] Univ London Imperial Coll Sci Technol & Med, Ctr Patient Safety & Serv Qual, London, England
关键词
Patient preference; decision-making; colorectal cancer; surgery; oncology; RECTAL-CANCER; PREOPERATIVE RADIOTHERAPY; DECISION-MAKING; ADJUVANT TREATMENT; TREATMENT OPTIONS; THERAPY; CHEMORADIATION; FLUOROURACIL; CHEMOTHERAPY; RECRUITMENT;
D O I
10.1111/codi.12754
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
AimThis systematic review aimed to assess the use of patient preference in colorectal cancer treatment. Eliciting patient preference is important for shared decision-making in colorectal cancer treatment. The introduction of newer treatments, which balance quality of life and overall survival, makes this an important future focus. MethodA systematic search strategy of MEDLINE, Embase, PsycINFO, CINAHL and the Cochrane Database for Systematic Reviews was undertaken to obtain relevant articles. Information regarding the type of patients included, preference instruments, study settings, outcomes and limitations was extracted. ResultsThe eight articles comprising this review each described an empirical study using a validated instrument to define patient preference for an aspect of colorectal cancer treatment. The evidence suggests that patients are prepared to trade significant reductions in life expectancy to avoid certain complications of colorectal surgery, particularly stoma formation. In the adjuvant setting, patients are prepared to risk significant treatment side effects to gain small potential increases in life expectancy and chance of survival. Where neoadjuvant or adjuvant treatment risks worsening function, however, patients generally forgo any potential increase in survival to improve bowel function and therefore quality of life. The only predictors of preference were tertiary education and previous cancer treatment. ConclusionMost patients judge a moderate survival benefit to be sufficient to make adjuvant therapy for colorectal cancer worthwhile, but they are willing to trade a potential reduction in life expectancy and survival to avoid certain unwanted surgical sequelae.
引用
收藏
页码:17 / 25
页数:9
相关论文
共 39 条
[1]
Early prostate cancer - which treatment do men prefer and why? [J].
Anandadas, Carmel N. ;
Clarke, Noel W. ;
Davidson, Susan E. ;
O'Reilly, Patrick H. ;
Logue, John P. ;
Gilmore, Lynne ;
Swindell, Ric ;
Brough, Richard J. ;
Wemyss-Holden, Guy D. ;
Lau, Maurice W. ;
Javle, Pradip M. ;
Ramani, Vijay A. C. ;
Wylie, James P. ;
Collins, Gerald N. ;
Brown, Stephen ;
Cowan, Richard A. .
BJU INTERNATIONAL, 2011, 107 (11) :1762-1768
[2]
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[4]
[Anonymous], 2009, SYST REV CRDS GUID U
[5]
[Anonymous], COCHRANE HDB SYSTEMA
[6]
[Anonymous], TRANS END MICR TEM R
[7]
Understanding surgical interventions in RCTs: the need for better methodology [J].
Avery, K. N. ;
Barham, C. P. ;
Berrisford, R. ;
Blazeby, J. M. ;
Blencowe, N. S. ;
Donovan, J. ;
Elliott, J. ;
Falk, S. J. ;
Goldin, R. ;
Hanna, G. ;
Hollowood, A. D. ;
Metcalfe, C. ;
Noble, S. ;
Sanders, G. ;
Streets, C. G. ;
Titcomb, D. R. ;
Wheatley, T. .
LANCET, 2013, 381 (9860) :27-28
[8]
Preferences for cancer treatments: an overview of methods and applications in oncology [J].
Blinman, P. ;
King, M. ;
Norman, R. ;
Viney, R. ;
Stockler, M. R. .
ANNALS OF ONCOLOGY, 2012, 23 (05) :1104-1110
[9]
Patients' preferences for chemotherapy in non-small-cell lung cancer: A systematic review [J].
Blinman, Prunella ;
Alam, Mahmood ;
Duric, Vlatka ;
McLachlan, Sue-Anne ;
Stockler, Martin R. .
LUNG CANCER, 2010, 69 (02) :141-147
[10]
Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile? [J].
Blinman, Prunella ;
Duric, Vlatka ;
Nowak, Anna K. ;
Beale, Philip ;
Clarke, Stephen ;
Briscoe, Karen ;
Boyce, Adam ;
Goldstein, David ;
Hudson, Malcolm ;
Stockler, Martin .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (10) :1800-1807